

<i>Highly Specialised Technologies (HST)</i>	<i>Date of HST Release</i>	<i>Adherence of local formulary to NICE</i>	
		<i>Included on the Trust Formulary for this indication</i> <i>Yes OR</i> <i>No</i>	<i>Reason provided if "No"</i>
2023-24			
HST24 - Onasemnogene abeparvovec for treating presymptomatic spinal muscular atrophy	19/04/2023	No	Not a NICE commissioned site
HST25 - Lumasiran for treating primary hyperoxaluria type 1	19/04/2023	No	Not a NICE commissioned site
HST26 - Eladocogene exuparvovec for treating aromatic L-amino acid decarboxylase deficiency	19/04/2023	No	Not a NICE commissioned site
HST27 - Afamelanotide for treating erythropoietic protoporphyria	26/07/2023	No	Not a NICE commissioned site